SCHEMBL267150

SCHEMBL267150

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(I)cc2C(=O)NN=Cc2ccc(OC)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.49
MAPT P10636 6/20 0.49
ALDH1A1 P00352 5/20 0.49
HPGD P15428 4/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
PKM P14618 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALOX12 P18054 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 2/20 0.43
SPHK2 Q9NRA0 2/20 0.43
SPHK1 Q9NYA1 2/20 0.43
SLC34A2 O95436 2/20 0.41
HIF1A Q16665 2/20 0.40
BCHE P06276 1/20 0.40
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267149 1.00 KDM4E (0.49) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL268019 0.95 KDM4E (0.51) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL268018 0.95 KDM4E (0.51) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL267157 0.93 SPHK2 (0.46) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL267156 0.93 SPHK2 (0.46) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL267591 0.92 MAPT (0.47) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL267590 0.92 MAPT (0.47) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL266015 0.92 MAPT (0.49) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL266014 0.92 MAPT (0.49) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL267406 0.92 NPC1 (0.45) KDM4EMAPTALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885MAPT 4195/4885ALDH1A1 3022/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885MAPT 4648/4885ALDH1A1 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.